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An executive functioning perspective in neurofibromatosis type 1:
from ADHD and autism spectrum disorder to research domains
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Abstract
Purpose Neurofibromatosis type 1 (NF1) is a rare monogenic disorder associated with executive function (EF) deficits and
heightened risk for attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The goal of this paper
is to understand how EFs provide a common foundation to understand vulnerabilities for ADHD and ASD within NF1.
Methods A literature review and synthesis was conducted.
Results EF difficulties in working memory, inhibitory control, cognitive flexibility, and planning are evident in NF1, ADHD, and
ASD. However, relatively little is known about the heterogeneity of EFs and ADHD and ASD outcomes in NF1. Assessment of
ADHD and ASD in NF1 is based on behavioral symptoms without understanding neurobiological contributions. Recent efforts
are promoting the use of dimensional and multidisciplinary methods to better understand normal and abnormal behavior,
including integrating information from genetics to self-report measures.
Conclusion NF1 is a monogenic disease with well-developed molecular and phenotypic research as well as complementary
animal models. NF1 presents an excellent opportunity to advance our understanding of the neurobiological impact of known
pathogenic variation in normal and abnormal neural pathways implicated in human psychopathology. EFs are core features of
NF1, ADHD, and ASD, and these neurodevelopmental outcomes are highly prevalent in NF1. We propose a multilevel approach
for understanding EFs in patients with NF1.This is essential to advance targeted interventions for NF1 patients and to advance the
exciting field of research in this condition.
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Introduction to neurofibromatosis 1
and related neurodevelopmental outcomes
Neurofibromatosis 1 (or NF1) is a neurocutaneous disorder
affecting 1 in 2700 live births [1]. Diagnostic criteria for
NF1 include at least two of the following: 6 or more caféau-lait macules, two or more neurofibromas or one plexiform
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neurofibroma, freckling in axillary region, optic glioma, multiple lisch nodules, distinctive osseous lesion, or a first-degree
relative with NF1 [2] (see [3] for a review of the clinical
phenotype). NF1 is caused by a pathogenic NF1 heterozygous
variant. The NF1 gene encodes for neurofibromin which negatively regulates the Ras pathway [3, 4].
NF1 research has grown exponentially in the last
20 years thanks to the common efforts of researchers,
funding agencies, private philanthropy, and advocacy
groups. The result is extensive new knowledge into the
neurobiology of the disease and further characterization of
the NF1 phenotype. The result, a recent FDA approved
treatment [5] for plexiform neurofibroma, brings hope for
many patients and families. In addition, new animal
models [6, 7] complement existing well-established NF1
models to increase opportunities for research and development of interventions. Despite this progress, molecularand disease-targeted interventions for cognitive deficits
remain elusive.

N F1 i n c r e a s e s r i s k f o r co g n i t i v e d e f i c i t s an d
neurodevelopmental disorders [8–11]. Research indicates a
characteristic “downward shift” in intellectual functioning,
where individuals with NF1 score approximately 1 standard
deviation below the general population (e.g., [12]) as well as
their unaffected siblings [13]. A minority of individuals with
NF1 show more severe intellectual deficits, with about 4–8%
of individuals with NF1 meeting criteria for an intellectual
disability [10, 13]. Youth with NF1 are much more likely to
develop attention deficit/hyperactivity disorder (ADHD) with
rates ranging from 38 to 67% [13, 14] and autism spectrum
disorder (ASD) with estimates ranging from 10.0 to 39.2%
using a broader phenotype [15, 16]. Specific learning disorders, such as dyslexia, are observed in 19 to 61% youth with
NF1 [13, 17]. Difficulties with motor coordination, planning,
weakness, and fatigue are also evident in NF1 [18].
Taken together, NF1 increases risk for various cognitive
and neurodevelopmental outcomes. These outcomes are
closely related to behavioral and social functioning which
are among the strongest predictors of quality of life in NF1
[19–22]. Therefore, it is important to understand factors that
contribute to these difficulties. The purpose of this paper is to
examine current research on executive function (EF) in the
NF1 population and how EF deficits may contribute to general
and specific vulnerability for neurodevelopmental difficulties
within NF1, with a focus on the clinical diagnoses of ADHD
and ASD. We will also review the limitations of this approach
and propose recommendations to advance clinical and translational research to improve NF1 interventions.

Fig. 1 A research domain approach to characterizing behavioral and
b
social phenotypes in NF1 across multiple levels. (a) Functional
outcomes. Individuals with NF1 exhibit increased functional
impairment in behavioral, social, emotional, and academic domains
and, relatedly, lower quality of life. (b) Diagnosis. NF1 greatly
increases the likelihood for both ADHD and ASD [4]. In the general
population, genetic and phenotypic correlations between ADHD and
ASD are substantive [4]. Within NF1, ADHD and ASD diagnostic
categories and symptom dimensions also overlap [16]. ADHD and
ASD are predictive of functional outcomes in NF1 (e.g., [24, 25]). (c)
Executive functions. Working memory, inhibitory control, cognitive
flexibility, and planning are interrelated executive functions [23] and
reduced in NF1 [26]. EF difficulties in these domains are also
associated with ADHD and ASD (Table 1) and likely contribute to
common and unique risk for diagnostic and functional outcomes. (d)
Neurobiology. The neurobiological underpinnings of EF and ADHD
and ASD diagnoses in NF1 are just beginning to be explored. The
dorsolateral prefrontal cortex, ventromedial prefrontal cortex, and the
dorsal/ventral anterior cingulate cortex are consistently associated with
EFs across typically and atypically developing populations. The
heterogeneity in functional connectivity in NF1 in frontoparietal,
frontostriatal, and ventral attention networks may alter EF profiles in
NF1. (e) Genetic/Molecular/Cellular. Pathogenic variants in NF1 alter
Ras signaling pathways with downstream effects on molecular and
cellular phenotypes [3, 4]. Differences at this level provide a foundation
for atypical neurodevelopmental trajectories

cortex (Fig. 1d; [13, 26, 31] and have been linked with academic, social and motor outcomes. The severity or variability
of NF1 also needs to be considered when examining EFs in
this population. For example, young patients with NF1 and an
optic pathway glioma or other CNS tumors show increased EF
difficulties compared to those without CNS tumors [32]. The
most common EFs affected/studied in NF1 patients are
discussed subsequently.

Executive function in youth with NF1
NF1 and working memory
Executive function (EF) refers to a set of interrelated skills that
are responsible for purposeful, goal-directed, problem-solving
behavior [23]. EF includes initiating goal-directed behavior,
inhibiting competing actions or stimuli, planning and selecting
relevant task goals, organizing behavior to solve complex
problems, flexible shifting of problem-solving strategies when
necessary, and monitoring and evaluating problem-solving
behavior ([23]; see Fig. 1c].
Extensive research has been done to try to understand the
magnitude of EF deficits in NF1 and the impact such deficits
have on cognition, behavior, and academic achievement.
Children with NF1 have deficits in multiple EF domains when
measured using daily life and laboratory measurement techniques [26]. Children and adults with NF1 exhibit extensive
EF compromise in working memory capacity, inhibition, cognitive flexibility and planning [26], with effects similar to
those found in ADHD and ASD samples (see Table 1).
Fluency or generativity is also lower in NF1 samples [30],
but it has received less attention in the NF1 literature. These
EFs are thought to be primarily mediated by the prefrontal

Working memory capacity plays a fundamental role in actively holding information in the service of problem solving [23].
Working memory difficulties are evident across the life span
in NF1 samples [33–35], with effect sizes in the moderate
range (Table 1). Differences between working memory skills
of youth with NF1 compared to controls may increase overtime [26]. A recent meta-analysis shows that verbal and
visual-spatial working memory are both negatively affected
in NF1, but verbal working memory may be relatively more
affected [26]. However, only two included studies examined
visual-spatial working memory thus results should be
interpreted cautiously. In NF1, working memory plays an important role in academic outcomes [36] and may allow some
to experience more benefit from educational supports like
phonics-based reading intervention [37].
Evidence from both NF1 ± mice and humans indicates
hypoactivation in frontoparietal and frontostriatal networks,
including the dorsolateral prefrontal cortex (dlPFC), which is
associated with working memory deficits in humans [38]. In
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adults with NF1, there is reduced functional connectivity in
the left dlPFC and the right parietal cortex [35], both implicated in the frontoparietal network. Adults with NF1 exhibit
increased activation relative to controls in the posterior cingulate cortex and temporal regions [35]. Within NF1, increased
connectivity between the posterior cingulate cortex and frontal

and parietal cortices is associated with increased working
memory performance [35]. Additionally, a pilot study found
that youth with NF1 demonstrated improved performance on
tasks related to attention and spatial working memory following 6–10 weeks of Cogmed—a cognitive training program
[39]. Improvements in cognitive outcomes were attributed to
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increased synchrony between the frontoparietal and visual
cortex [39].

NF1 and inhibitory control
Inhibitory control works in conjunction with working memory
to maintain progress towards one’s goal, by sustaining focused
attention and inhibiting behavioral and cognitive responses
that are inconsistent with one’s goal [23]. Meta-analysis indicates that individuals with NF1 have small but significant
reduction in inhibitory control, relative to controls [26]. The
magnitude of effect of NF1 on types of inhibitory control is
similar, including interference control/cognitive inhibition,
selective/focused attention, and response inhibition [26].
Inhibitory control deficits in NF1 are found in those with
and without ADHD comorbidity [40]. The developmental
course of deficits in inhibitory control in NF1 is not well
known.
Difficulty with inhibitory responses in NF1 is associated
with decreased white matter integrity within the anterior thalamic radiations within the fronto-striatal circuit [41]. In addition, NF1-related inhibitory control difficulties are associated
with decreased functioning in the pre-supplementary motor
area, fusiform gyrus/posterior cerebellum, and the inferior occipital gyrus [42]. Additionally, in NF1, the ventral attention
network is linked with attentional control and selective attention difficulties [43]. Elevated medial frontal GABA is also
associated with increased response speed in NF1 and decreased response speed in controls [44]. Altered GABA/
glutamate ratios have also been linked to NF1-related cognitive deficits [4, 45–47], and abnormal frontal GABA physiology in NF1 may be of particular importance to inhibitory
control [44]. Hypofunctioning of mesolimbic dopaminergic
pathways is associated with GABA/glutamate imbalance in
NF1 [48]. This may contribute to differences in frontostriatal
circuit function in NF1 and attentional difficulties within NF1
animal models [49, 50].

indicating the deficits in cognitive flexibility in NF1 are not
merely a function of other related EF weaknesses [30]. To our
knowledge, no studies have investigated the neurobiological
origins of cognitive flexibility specifically in NF1.

NF1 and planning and problem solving
Higher-order EF processes, like planning and problem solving, are influenced by working memory, inhibitory control,
and cognitive flexibility [23]. Planning is a complex construct
and includes the ability to think ahead and consider consequences of actions or the sequencing of steps to accomplish
a goal [52]. Planning and problem-solving skills are significantly lower in youth with NF1 relative to controls and in the
moderate range (Table 1), but there is significant heterogeneity in effect sizes between studies [26]. It is currently unclear
which sample or methodological factors are associated with
variability in effect size. Differences in planning between NF1
and controls are not solely due to cognitive flexibility, visualspatial reasoning, and/or ASD behavioral symptoms [30],
suggesting deficits in planning skills are independent of other
factors in NF1. Planning skills in NF1 youth may also be
related to academic skills [36].
Youth with NF1 also experience difficulty with motor
planning, motor coordination, and reduced muscle strength
and fatigue [53–55]. EF planning deficits are associated with
laboratory measures of motor planning [54], thus weaknesses
in EF planning may contribute to motor difficulties observed
in this population or vice versa. The impact of how motor
deficits and cognitive skills influence one another on tasks
that need a mediated motor output is not well understood in
NF1. However, motor impact in NF development and cognition is beyond the scope of this paper.
Across a range of non-NF1 samples, planning appears to be
a bilateral process involving the dlPFC, frontal eye fields,
supplementary motor area, precuneus, caudate and anterior
insula, and inferior parietal cortex [56], which have been implicated in other EFs within NF1 samples.

NF1 and cognitive flexibility
Working memory and inhibitory control contribute to cognitive flexibility which promotes switching between tasks, perspective taking, and utilizing a range of problem-solving approaches [23]. Cognitive flexibility also provides a
neurocognitive foundation for creativity and theory of mind
[23]. In youth with NF1, cognitive flexibility skills are lower
compared to controls and the effect size is small [26]. In particular, youth with NF1 demonstrate more difficulty with reactive flexibility—or adapting problem solving behavior in
the context of inconsistent environmental responses [51].
These differences are related to ASD-associated behaviors
[30]. Deficits in cognitive flexibility remain after controlling
for IQ [51] and spatial working memory and inhibition [30],

Summary of executive functions in NF1
Taken together, specific EF deficits in NF1 are present across
the lifespan. Deficits in working memory and planning/
problem solving are in the moderate range, whereas deficits
in inhibitory control and cognitive flexibility are slightly
smaller (Table 1). Frontoparietal, frontostriatal, and ventral
attention networks are implicated in the neural pathways mediating EF networks in NF1; however, research investigating
the neural correlates of specific EFs in NF1 has been largely
limited to the working memory [35, 38] and inhibitory control
domains [41–43]. EF difficulties in NF1 are associated with
decreased academic [36], motor [54], and social functioning

[30]. Comparing EF outcomes between NF1, ADHD, and
ASD samples may be the first step to increase our understanding of common and unique neurocognitive risk in NF1.
However, to guide diagnosis and treatment, EFs should be
integrated in a multi-level phenotypic characterization from
genomics and circuits to behavior and self-reports, in order
to explore basic dimensions of functioning.

Executive functions in ADHD and ASD
in the general population
Both ADHD and ASD are considered neurodevelopmental
disorders with onset in childhood, and although causal links
are currently unknown, both disorders are highly heritable
with approximately 64–91% of both phenotypes being
accounted for by genetics [57, 58]. ADHD and ASD symptom
dimensions are correlated at both a phenotypic and genetic
level [4]. Genetic correlations between ADHD and ASD
symptom dimensions range from 0.33 to 0.56 [59, 60].
ADHD is characterized by elevated levels of inattention
and/or hyperactivity/impulsivity in comparison to same-aged
peers [61]. EF deficits largely contribute to the ADHD behavioral phenotype [62–64]. Relative to controls, individuals with
ADHD demonstrate weaknesses in working memory, response inhibition, sustained attention, cognitive flexibility,
planning, and fluency/generativity [27, 65]. However, the severity of EF deficits in ADHD varies by age and type of
assessment [65, 66].
Alterations in the fronto-dorsal striatal network are related
to disruptions in the mesocortical dopaminergic pathway [67,
68]. Additionally, altered reward circuitry, which is linked to
the mesolimbic dopaminergic pathway, is associated with delay aversion contributing to impulsivity, inattention, or hyperactivity, depending on context [67, 68]. EF deficits in ADHD
youth are related to hypoactivation in the frontoparietal and
ventral attention networks, with increased activation also observed in the default, ventral attention, and somatomotor networks [69, 70].
ASD is characterized by social communication difficulties
and restricted interests/repetitive behaviors. ASD is a highly
heterogeneous disorder in symptom presentation and severity
level. However, EF deficits in ASD are common and include
weaknesses in working memory, inhibitory control, cognitive
flexibility, planning, fluency, and concept formation [28],
with effects in the moderate range across EF domains
(Table 1). EF deficits in ASD appear to be largely stable
across development [28], observed in individuals with ASD
without intellectual disability [29, 71, 72], and are negatively
associated with quality of life [73]. Additionally, variation in
EF skills account for some phenotypic heterogeneity within
ASD, including in social functioning [74], restricted interests/
repetitive behaviors [75], disruptive behavior [71], and theory

of mind [76]. Approximately 28% of individuals with ASD
also experience comorbid ADHD, among other comorbid disorders which are associated with EF impairments [77].
Data from a pooled resting-state fMRI analysis indicates
that individuals with ASD exhibit corticocortical and interhemispheric functional hypoconnectivity, as well as
hyperconnectivity in local subcortical circuits [78]. This indicates that during EF tasks individuals with ASD may prioritize
the engagement of subcortical local circuits over long-range
circuits [79]. Increased hyperconnectivity in ASD is associated with greater impairment [80]. Additionally,
hypoconnectivity within frontoparietal and ventral attention
networks is associated with ADHD symptoms in ASD [81].

ADHD and ASD in NF1: the role of executive
function
From a clinical perspective, it is clear that EF deficits are
central to the comorbidity between NF1 and
neurodevelopmental outcomes that affect quality of life. EF
impact is not specific to academic performance but spans multiple domains of functioning (Fig. 1), from social interaction to
economic independence. Traditional clinical assessments often measure EF functioning to inform diagnostic clarification,
often related to ADHD, ASD or learning disabilities. While
this categorical approach helps patients and families to access
services and remediation interventions, it provides very little
information about neuroscience and the neurobiological underpinnings of these manifestations. However, as this approach is the one that is currently used, we will summarize
the findings from the limited studies examining EF deficits in
patients with NF1 and ADHD and or ASD symptomatology.

NF1 and ADHD
In the NF1 population, ADHD diagnosis has been reported to
be between 38 and 67% [13, 14]. Those individuals are expected to have a more complex profile of EF and attention
deficits than do the NF1 patients without an ADHD diagnosis.
In addition, the presence of ADHD has been found to be a
major risk factor for poor social functioning [11, 25, 82], as
well as poor general intellectual functioning [14, 83].
Although there is evidence that cognitive control deficits are
not limited to NF1 patients with comorbid ADHD [40, 84],
children with both disorders are acknowledged as among the
most severely affected in terms of academic performance, social interactions, and behavioral problems [11, 14, 25].
Children with NF1 with concomitant diagnosis of ADHD
experience significant deficits in visual and verbal working
memory [85]. Working memory is a particularly compelling
target for intervention, given its critical role in the development of most cognitive and academic outcomes. In healthy

children, it has been suggested that developmental increases in
IQ are associated with age-related improvements in working
memory and processing speed [86]. Because working memory capacity increases two- to three-fold from age 4 to 16 [87],
disruption of the development of these processes can significantly curtail a wide range of the child’s abilities over time.
This may take the form of diminished IQ or difficulty with
other aspects of EF and academic performance. For example,
children with reading difficulties frequently have deficits in
working memory that appear to contribute to problems with
phonological memory [88, 89]. Math skills are also strongly
linked to working memory capacity in typically developing
children accounting for 20–57% of the variance in math performance [88, 90].
From a developmental perspective, it is reasonable to hypothesize that improving working memory in children with
NF1 may help to offset problems with IQ, EF, and academic
performance over time. Computerized working memory training interventions that have been tested on multiple neurological conditions to increase working memory are currently being tested on patients with NF1 [91]. If proven beneficial,
these interventions may be used during the developmental
periods to improve working memory, and have downstream
effects on cognitive domains and functioning across domains.
Assessment and interventions targeting improvements in EF
should include patients from pre-school age to early adulthood
given findings that EF deficits persist into adulthood in NF1
[25, 34, 82].

NF1 and ASD
Parent and teacher report indicate that children with NF1 exhibit significant social functioning difficulties. They are perceived as socially isolated or sensitive as well as displaying
less leadership behaviors [11, 16, 92]. Youth with NF1 show
higher levels of autistic traits or meet full diagnostic criteria of
ASD [15, 16]. For example, 44% of an NF1 sample demonstrated restricted and repetitive behaviors at least one standard
deviation above the mean [11]. Additionally, problems with
flexibility, transitions, and manifestations [92]. Impairment in
social communication and lack of motivation in social interactions are reported in at least 30% of these children. From a
neuropsychological perspective, these symptoms may be due
to the complex dysfunction of frontal lobe pathways and EF
alterations [93]. It is clear that ASD diagnosis in NF1 is not a
homogenous profile and may differ significantly from ASD
expression in non-NF1 samples.
The International NF1-ASD Consortium Team (INFACT)
was created to further understand the significantly elevated
rates of ASD symptomatology seen in NF1 samples. A
multi-site analysis of 531 individuals with NF1 found that
patients exhibited a significant burden of autistic traits and
symptoms along a continuous distribution that encompassed

the full range of severity, from mild (subclinical) to severe
(clinical) [16]. The consortium sample confirmed that more
than 13.2% presented with severe symptoms of ASD and
more than 43.2% were above the threshold scores for an
ASD diagnosis. When NF1 was inherited, there was a high
degree of within family association for the severity of autistic
traits. Research into the biological mechanisms impacting
these social deficits is currently on-going [47, 94].
The characterization of the behavioral and cognitive phenotype, genetic correlations and potential translation into therapeutics is an essential next step for the NF1 population. Of
special interest is improving our understanding of cognitive
flexibility—a key EF component. Difficulty with cognitive
flexibility is also observed in NF1-related comorbidities, like
ASD [95, 96] and anxiety [97, 98]. Difficulties with cognitive
flexibility may contribute to increased externalizing and internalizing behavior [99, 100], especially in the context of parental inconsistency [101]. Thus, the interaction between cognitive flexibility and inconsistent contingency management in
the environment may be one pathway to increased behavioral
or emotional dysregulation in the NF1 population.
In summary, current advances in our understanding of increased rates of ASD symptomatology in patients with NF1
have demonstrated that the association between the syndromes is real and most likely associated at the genetic level.
However, we have only taken the first steps into a completely
novel field that has the potential to yield an abundance of
research possibilities. By analyzing phenotypes and genetic
correlations and weighing potential pharmacological and
non-pharmacological interventions, we can continue to explore this relationship and the correlations with other genetic
conditions as well.

Discussion
The goal of this paper is to examine the impact that EFs have
on the profile of neurodevelopmental outcomes in patients
with NF1. At a group level, EF difficulties in NF1 are diffuse
across EF domains, with moderate deficits in working memory and planning/problem solving domains and smaller deficits in inhibitory control and cognitive flexibility domains
[26]. Evidence from NF1 human and animal studies implicates frontoparietal and frontostriatal circuitry working memory functioning [35, 38, 39] and frontostriatal and ventral attention circuits in inhibitory control functioning [41–43]. EFs
serve as a putative mechanism underlying the relationship
between NF1 and ADHD and NF1 and ASD and allow us
to understand variability in ADHD and ASD within the NF1
population.
It is essential that we advance our understanding of the
neurobiological variability of neural pathways, molecular
and genetic factors that impact NF1. This will improve our

ability to develop targeted molecular interventions for cognitive deficits in this population. However, doing so requires a
shift away from using a categorical framework for ASD and
ADHD diagnosis and towards a detailed phenotypic evaluation (neuropsychological testing plus behavioral scales) in
conjunction with objective neuro-biological assessments
(i.e., fMRI, resting state fMRI, and genetic pathways; [102]).
Limitations and future directions for research First, differences in EF measurement between studies and limited reliability of single EF domain measures limit our ability to compare
and replicate findings. The neurocognitive committee of the
Response Evaluation in Neurofibromatosis and
Schwannomatosis (REiNS) International Collaboration has
provided guidance on measurement within the domain of attention [103] which should support measurement consistency
between studies. Additionally, a latent factor approach with
multiple indicators of EF domains will aid in the reduction of
measurement error and improve replicability across studies
[104]. Second, the majority of EF and cognitive research in
NF1 is from case-control designs and analyses within NF1
samples are limited by sample size. These group-based EF
differences may not apply to individual-level data, which limit
their utility in understanding how to tailor intervention to individual NF1 cases. More analysis examining EF profiles or
clusters within NF1 and linking these across multiple levels
(e.g., neurofunctional and behavioral) are needed [24, 105].
Larger sample sizes and multidimensional and multidisciplinary research approaches need be strongly supported [8]. Third,
neurobiological studies of EF in NF1 are limited to working
memory and inhibitory control/attentional domains. The field
would benefit from studies to extend our understanding of
which neural circuits underpin EF cognitive flexibility, planning, and fluency/generativity domains. Important efforts are
being made to improve our understanding of the neurobiological underpinnings of psychiatric and cognitive conditions
[102, 106].
Implications of multilevel phenotyping A multi-level characterization of EF in NF1 (see Fig. 1) will help to provide an
understanding of targets for interventions and ways to tailor
intervention to individual cases. EFs may provide a general
target to improve behavioral, social and academic functioning
in the NF1 population. Given high prevalence rates of multiple neurodevelopmental disorders in NF1 and their comorbidity, EF provides a common or shared vulnerability target,
which may help to maximize improvement across multiple
domains of functioning.
Significant advances in the understanding of functional
neural circuits implicated in brain function in patients with
NF1 have been made. Using resting state fMRI, small studies
have shown an overall decrease of the short and long-distance
connectivity in the default network in patients with NF1

compared with typically developing controls [107]. In addition, changes in brain connectivity were observed after
12 weeks of treatment with lovastatin [107] and after computer training intervention for working memory [39]. A recent
translational research study comparing brain functional connectivity in animal models of NF1 and patients with diagnosis
of NF1 showed that decreased connectivity using resting state
fMRI is a feature that is present in animals and patients carrying the NF1 mutations [108]. Additionally, the biological correlation between NF1 animal models and humans can be used
to advance testing for medications and other interventions into
clinical trials. However, correlations with high order cognitive
function may require better phenotyping into complex models
that allow understanding from the molecular pathway to the
clinical manifestations.
Taken together, EF difficulties play an important role in the
overall cognitive difficulties in NF1 and a core role in the
social and behavioral profiles in this population; however,
they are not fully understood [30]. We need to better understand the impact of EF deficits on these neurodevelopmental
outcomes in individuals with NF1 beyond current DSM categorical diagnosis. As we better understand the neurobiology
of EFs in individuals who are typically developing and those
with developmental and neurodevelopmental disorders, we
can better translate our knowledge to specific neurogenetic
disorders like NF1.
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